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HIV envelope glycoprotein (Env) is the target for inducing neutralizing antibodies. Env is present on the virus surface as a trimer, and, upon
binding to CD4, a cascade of events leads to structural rearrangement exposing the co-receptor binding site and entry into the CD4+ host target
cells. We have designed monomeric and trimeric Env constructs with and without deletion of the variable loop 2 (ΔV2) from SF162, a subtype B
primary isolate, and performed biophysical, biochemical and immunological studies to establish a potential structure–functional relationship. We
expressed these Envs in CHO cells, purified the proteins to homogeneity and performed biophysical studies to define the binding properties to
CD4, structural characteristics and exposure of epitopes recognized by b12 and CD4i mAb (17B) on both full-length and mutant HIV Env
proteins. Parameters evaluated include oligomerization state, number and affinity of CD4 binding sites, enthalpy and entropy of the Env–CD4
interaction and affinity for b12 and 17b mAbs. We observed one CD4 binding site per monomer and three active CD4 binding sites per trimer. A
40-fold difference in affinity of the gp120 monomer vs. the o-gp140 trimer towards CD4 was observed (Kd = 58 nM and 1.5 nM, respectively),
whereas only a 2-fold difference was observed for the V2 deleted Envs (Kd of gp120ΔV2 = 19 nM, Kd of o-gp140DV2 = 9.3 nM). Monomers
had 3-fold higher affinity to the mAb 17b and at least 3-fold weaker affinity to b12 compared to trimers, with gp120DV2 having the weakest
affinity for b12 (Kd = 446 nM). Affinity of CD4 binding correlated with proportion of the antibodies induced against the conformational epitopes
by the corresponding Envs, and changes in mAb binding correlated with the induction of antibodies directed against linear epitopes. Furthermore,
biophysical analysis reveals that the V2 deletion has broad structural implications in the monomer not shared by the trimer, and these changes are
reflected in the quality of the immune responses induced in rabbits. These data suggest that biophysical characteristics of HIV Env, such as affinity
for CD4, and exposure of important neutralizing epitopes, such as those recognized by b12 mAb, may be important predictors of its in vivo
efficacy and may serve as important surrogate markers for screening Env structures as potential vaccine candidates.
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doi:10.1016/j.virol.2006.04.030human immunodeficiency virus (HIV) and 25 million deaths
due to AIDS recorded so far. In North America today, an
estimated 1.2 million individuals are living with HIV, and
43,000 new primary infections occurred last year (UNAIDS/
WHO, 2004). Moreover, the situation is continuously deterio-
rating as a result of rapid emergence of drug resistance against
most of the effective anti-virals. Therefore, there is an urgent
need for an effective anti-HIV vaccine that may be used alone as
a prophylactic vaccine or in conjunction with effective anti-
virals as a therapeutic vaccine.
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antibody responses against diverse primary HIV-1 isolates by
utilizing monomeric HIV Env (i.e., gp120) (Barnett et al., 1997;
Bou-Habib et al., 1994; Burton, 1997; Mascola et al., 1996;
Moore et al., 1995; Moore and Ho, 1995; Moore and Sodroski,
1996; Parren et al., 1997, 1999; VanCott et al., 1995; Wentworth
et al., 1994; Wrin et al., 1994; Wrin and Nunberg, 1994). Yet,
primary isolate neutralizing antibodies are induced during the
natural infection (Cao et al., 1995; Stamatos et al., 1998).
Therefore, there are differences between the quality of
antibodies induced during the infection and the quality of
those induced through vaccination using gp120. It appears that
this is not due to the absence of conserved neutralization
epitopes on gp120 (Steimer et al., 1991). However, the level of
exposure of these epitopes may be different on gp120 compared
to their exposure on native Env trimers present on virion
(Kwong et al., 1998; Moore et al., 1995; Parren et al., 1999;
Sattentau and Moore, 1995; Stamatatos and Cheng-Mayer,
1995; Wyatt et al., 1998).
In general, compared to non-neutralizing monoclonal anti-
bodies (mAb), neutralizing mAb such as b12, 2G12 and 2F5
appears to have stronger affinities for the native envelope
(trimer) (Burton et al., 1994; Fouts et al., 1997; Roben et al.,
1994; Sattentau and Moore, 1995; Sattentau et al., 1995;
Sullivan et al., 1995; Trkola et al., 1996b), suggesting that the
neutralizing epitopes recognized by these mAbs are better
presented on native trimeric Env. Therefore, efforts have been
made to purify HIV Env in trimeric conformation and evaluate
its ability to induce primary isolate-neutralizing antibodies in
animal models. Earlier studies suggested that HIV Env
oligomers, consisting of gp120 and the ectodomain of gp41,
might be superior to gp120 for inducing strong humoral
responses directed toward conformational epitopes (Broder et
al., 1994; Earl et al., 1994; Pinter et al., 1989; Putney et al., 1986;
Richardson et al., 1996; VanCott et al., 1997). In addition,
antibodies induced by oligomeric Env cross-reacted with HIV
Envs of other subtypes and neutralized both T-cell-adapted
(TCLA or X4) and selected primary HIV-1 isolates (R5) (Earl et
al., 2001; VanCott et al., 1997; Yang et al., 2001). Recent
evidence has demonstrated that oligomers may be superior to
monomers at inducing primary isolate-neutralizing antibodies
(Earl et al., 2001; VanCott et al., 1997; Yang et al., 2001),
suggesting that trimeric HIV Env has the potential to be effective
in inducing broadly cross-reactive neutralizing antibodies.
Little structural information is available on HIV Env to
predict and design novel immunogens that may induce
antibodies of appropriate specificity and protective efficacy
(Pantaleo and Koup, 2004). Based on the available 3-D
structure of gp120, it is evident that the heavily glycosylated
face of Env is immunologically silent (Kwong et al., 1998),
suggesting that the virus is using glycosylation for shielding
critical functional epitopes. Furthermore, we and others have
shown that glycosylation is needed for Env to attain functional
conformation (Barr et al., 1987; Lasky et al., 1987; Li et al.,
1993; McDougal et al., 1986; Papandreou et al., 1996; Putney et
al., 1986; Sanders et al., 2000; Sattentau and Weiss, 1988;
Scandella et al., 1993) since non-glycosylated Env (Env 2–3)does not bind to CD4 (Abrignani et al., 1990; Haigwood et al.,
1990). Recent evidence from SIV and SHIV rhesus infection
models suggests that the emergence of viruses resistant to
antibody mediated neutralization is associated with modifica-
tion of the glycosylation profiles and that resistance is, at least
partially, due to the alteration in the glycosylation sites within
Env (Back et al., 1994; Cheng-Mayer et al., 1999; Johnson and
Desrosiers, 2002; Ly and Stamatatos, 2000; Lue et al., 2002;
Narayan et al., 1999; Overbaugh and Rudensey, 1992; Over-
baugh et al., 1991; Reitter et al., 1998; Rudensey et al., 1998).
Therefore, the challenge is to minimize the level of glycosyl-
ation in order to enhance the exposure of functionally relevant
epitopes while preserving the structure of Env.
We hypothesized that Env is more immunogenic in its native
trimeric conformation and that, by introducing a V2 loop
deletion, we may further enhance its immunogenicity or its
ability to induce better neutralizing antibodies due to the
exposure of functional epitopes (Cao et al., 1997; Stamatatos
and Cheng-Mayer, 1998). Towards this end, we have
demonstrated that the ΔV2 trimer derived from SF162 (o-
gp140ΔV2) induced antibodies that neutralized 5 of 7 primary
isolates tested (Barnett et al., 2001). Furthermore, rhesus
macaques immunized with o-gp140ΔV2 SF162 in a DNA
prime and protein boost regimen demonstrated blunting of the
acute phase viremia upon challenge with pathogenic SHIV-
SF162P4. These animals were able to control their viremia with no
sign of disease for at least 900 days after challenge (Barnett et
al., 2001; Cherpelis et al., 2001a; Cherpelis et al., 2001b).
To increase our understanding of the structural properties of
HIV Env and their impact on the quality and magnitude of
antibody responses, we have performed detailed biophysical,
biochemical and immunological characterization of Env. Here,
we describe the purification and characterization of different
Env variants and compared their properties such as affinity and
thermodynamics of CD4 binding, epitope exposure and
structural rearrangement to establish a structure–function
relationship that may be useful in the design and development
of effective Env-based HIV vaccine.
Results
Purification of HIV-1 SF162 envelope glycoproteins
Four different soluble HIV-1 Envs (Fig. 1A) from SF162, a
subtype B isolate, were expressed as monomers (gp120 and
gp120ΔV2) as well as trimers that included the gp120 and the
extracellular parts of gp41 (o-gp140 and o-gp140ΔV2) in CHO
cells and purified as described elsewhere in detail (Srivastava et
al., 2002, 2003). The protease cleavage site between gp120 and
gp41 was eliminated to stabilize Env in trimeric conformation
as described earlier (Srivastava et al., 2003). Purity and identity
of all four Envs were confirmed using SDS-PAGE (Fig. 1B),
Western analysis (Fig. 1C) and qualitative CD4 binding (data
not shown). Gel filtration and SDS-PAGE analyses confirmed
that purity of all four proteins was >90%. Furthermore, we
analyzed the glycosylation profiles of the purified Envs by
digesting the purified Env with different glycosidases and
Fig. 1. (A) Schematic diagram of the SF162 envelope structures generated, purified and used in this study. All constructs contain the variable domains V1 and V3–V5,
whereas only the full-length gp120 and full-length o-gp140 proteins contain the V2 loop. gp41, the transmembrane domain, and the intracellular domain were deleted
to yield soluble versions of the envelope protein. For creating the trimers either with or without V2 loop, the primary and secondary protease cleavage sites were
modified as described elsewhere (Srivastava et al., 2004). (B) The purified proteins were analyzed by SDS-PAGE, lane 1—molecular weight standards, lane 2—o-
gp140ΔV2, lane 3—o-gp140, lane 4—gp120ΔV2, and lane 5—gp120. (C) Immunoprobing of purified proteins, lane 1—molecular weight standards, lane 2—o-
gp140ΔV2, lane 3—o-gp140, lane 4—gp120ΔV2, and lane 5—gp120. (D) Glycosidic linkage analysis of purified proteins treated with different glycosidases, lanes
1, 7, 13 and 19 are molecular weight standards (1—250 kDa, 2—160 kDa, 3—105 kDa, 4—75 kDa, 5—50 kDa, 6—35 kDa).
133V.A. Sharma et al. / Virology 352 (2006) 131–144demonstrated that all forms of Env have predominantly N-
linked glycosylation (Fig. 1D). Endo H digestion of purified
Envs revealed that different Envs had similar levels of terminal
mannoses (Fig. 1D). Oligomerization state was assessed by size
exclusion chromatography (SEC) (Fig. 2) and triple detector
analysis (data not shown). All four Envs were highly
homogenous, gp120 and gp120ΔV2, were >90% monomeric,
while the trimers, o-gp140 and o-gp140ΔV2, were >95%
trimeric.
Affinity of Env for CD4: direct binding
Affinity of CD4 binding to different Envs was determined
using surface plasmon resonance (SPR). Flowing Env over a
chip coupled to CD4 (Fig. 3) revealed a slow rate of association
(kon = 10
4 M−1 s−1), indicating a large conformational change in
Env upon binding to CD4. By measuring the association and
dissociation rates at several Env concentrations, we determined
the apparent affinities of different Envs for CD4 (Table 1).
gp120, o-gp140 and o-gp140ΔV2 yielded a similar magnitudeof binding as reflected by response units (RU) at the same molar
concentration (Figs. 3A, C, D). However, gp120ΔV2 showed
a higher magnitude of binding to CD4 (higher RU) at the
same concentration of analyte (Fig. 3B versus A). Trimeric
o-gp140 bound to CD4 approximately 40 times tighter than
the monomeric gp120, however, the difference between
gp120ΔV2 and o-gp140ΔV2 is only 2-fold (Table 1).
gp120ΔV2 yielded a Kd similar to that of gp120, however,
compared to other Envs, the model did not fit the data well
as evidenced by the high χ2 value (Table 1) and systematic
residuals (data not shown).
Affinity of Env for CD4: indirect binding
To confirm the apparent affinities obtained for Env to CD4
by SPR, we did the converse experiment by capturing the Env
on chip and using CD4 as an analyte. The Kd values observed in
this experiment for all the Env with the exception of gp120ΔV2
were in agreement to those observed in the reverse experiment
(above) where Env was used as an analyte and CD4 was used as
Fig. 2. Size exclusion profiles of Envs after the final purification step (A) gp120
SF162, (B) gp120SF162ΔV2 and (C) o-gp140SF162 demonstrating that all
proteins are >90% homogenous and of the predicted size. The size exclusion
profile for o-gp140ΔV2 is presented in panel 2 of Fig. 5A.
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as a ligand (data not shown).
Thermodynamics of the Env–CD4 interaction
We used ITC to determine the stoichiometry and affinity of
binding for Envs to CD4 and also to gain insight into theFig. 3. CD4 binding of Env proteins using BIAcore: (A) gp120, (B) gp120ΔV2, (C
triplicate using 1000 RUs of four domain CD4 coupled to a CM4 sensor chip. The con
prepared by subtracting binding responses obtained from a BSA reference surface fthermodynamics of the interaction in the aqueous state. The
binding isotherms obtained (Fig. 4) were analyzed to determine
affinity of association (Ka) as well as enthalpy (ΔH), entropy
(reflected as −TΔS) and change in Gibbs free energy (ΔG)
(Table 1).
High enthalpies favoring binding were measured for the
Env–CD4 interactions (Table 1), suggesting that multiple
binding interactions occur during complex formation. Large
differences in the binding enthalpies for CD4 between
different Envs were also observed. Interestingly, o-gp140
produced the lowest enthalpy favoring association
(ΔH = −14 kcal/mol), whereas gp120ΔV2 produced the
largest enthalpy favoring association (ΔH = −40 kcal/mol).
gp120ΔV2 and o-gp140ΔV2 both produced a binding
enthalpy ∼4 kcal larger than their corresponding V2 intact
Envs.
A large change in entropy opposing binding to CD4 for
all the four Envs tested was observed (Table 1), suggesting
that significant molecular rearrangement takes place during
the binding phase and results in loss of structural freedom.
When comparing the calculated Gibbs free energy, enthal-
py–entropy compensation is observed as the CD4–envelope
complexes yield interaction energies favoring association and
differing by only 1 kcal/mol (Table 1).
The specific activity of gp120, o-gp140 and o-gp140ΔV2
was high (>80%) as reflected by the calculated active sites
(n values). The gp120ΔV2 monomer appears to be 50%
active in this assay (Table 1). Note that the number of
active CD4 binding sites (n value) for the trimers cannot be
determined by inspection of the x axis of the titration (Fig.
5) as the analysis software calculates the x axis as the molar
ratio of titrant to ligand (Env to CD4 in this case—see
Materials and methods).) o-gp140 and (D) o-gp140ΔV2. All measurements were taken in duplicate or
centration ranges for HIV Env analytes were 5 to 1000 nM. Biosensor data were
rom the specific responses.
Table 1
Kinetic and thermodynamic parameters of Env–CD4 binding as determined by SPR and ITC
SPR measurements
CD4 ligand, Env analyte Env ligand, CD4 analyte ITC measurements
Ka (1/μM) Kd (nM) χ2 Ka (1/μM) Kd (nM) Ka (1/μM) ΔH (kcal/mol) −TΔS
(kcal/mol)
ΔG
(kcal/mol)
n
gp120 17 58 7.8 30 33 5.3 ± 0.4 −36 ± 0.5 26 −9 0.8 ± 0.01
gp120ΔV2 53 19 50.3 ND ND 11.0 ± 1.4 −40 ± 0.9 30 −10 0.5 ± 0.01
o-gp140 667 1.5 1.5 238 4.2 4.2 ± 0.4 −14 ± 0.2 5 −9 2.9 ± 0.04
o-gp140ΔV2 108 9.3 9.3 106 9.4 2.1 ± 0.2 −18 ± 0.3 9 −9 3.3 ± 0.05
Affinity (Kd) was measured by analyzing multiple concentrations of analyte in SPR experiments and fitting the sensorgrams to one set of parameters. Affinity (Ka),
enthalpy (ΔH), entropy (expressed as −TΔS) and number of CD4 binding sites (n) were determined by analyzing ITC titrations. All data reported were repeated in
duplicate or triplicate.
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We first determined the stoichiometry of binding of
different Envs to CD4 using ITC. Initial analysis of the data
revealed potential heterogeneity in the material. Therefore, we
analyzed post-titrated ITC materials by size exclusion
chromatography (SEC-HPLC) to determine the concentration
of active vs. aggregated fraction of Env (data not shown). We
observed that as much as 20% of the concentrated Envs protein
was aggregated consistent with the n values observed, except
in the case of the gp120ΔV2 monomer which yields an n value
of 0.5 by ITC (Table 1), but appears to be at least 80%
monomeric by post-titration SEC-HPLC (data not shown).
After adjusting the active concentration of different Envs to
reflect the active concentration determined by SEC-HPLC, the
ITC data yielded appropriate number of CD4 binding sites (n)
for each Env (n = 1 for gp120 and gp120ΔV2 and n = 3 for
o-gp140 and o-gp140ΔV2).
We confirmed our results for stoichiometry of binding by
SEC-HPLC using different ratios of Env to CD4. Chromato-
grams of a titration for o-gp140ΔV2 are shown in Fig. 5A.
Using a molar excess of Env compared to CD4 yielded a
dominant peak corresponding to the free trimer (panel 3). As
additional CD4 was added, the retention time of the dominant
peak shifted to a larger species corresponding to an Env–CD4
complex. At a molar ratio of 3 CD4 molecules:1 trimer, we
did not observe any free CD4, indicating that all three CD4
binding sites in o-gp140ΔV2 were saturated. Titrations of
CD4 against all other Envs yielded similar results, i.e.,
monomeric Envs (gp120 and gp120ΔV2) bound to a single
CD4, whereas trimeric Envs (o-gp140 and o-gp140ΔV2)
bound three CD4s (Fig. 5B). Reverse titrations where the CD4
concentration was kept constant confirmed the data obtained
(data not shown).
Characterization of envelope proteins by monoclonal antibody
binding
We monitored the exposure of the CD4 binding site and
the CD4 inducible site in the different Envs using mAbs
b12 (Kessler et al., 1997; Trkola et al., 1996a, 1998) and
17b (Thali et al., 1993). All four Envs bound to b12; data
for gp120 (Fig. 6A) and o-gp140 (Fig. 6B) are shown.Kinetic data indicate that both trimers exhibited nanomolar
binding to b12 (Table 2), consistent with previously reported
results (Barbas et al., 1992). However, gp120 exhibited a 3-
fold weaker affinity for b12 compared to o-gp140. The
apparent affinity of gp120ΔV2 for b12 was 70-fold weaker
compared to o-gp140ΔV2 (Table 2). gp120ΔV2 consistently
yielded a two-fold higher RU value compared to gp120 at
the same concentration (data not shown), however, this
difference was not observed for o-gp140ΔV2.
All four Envs bound to 17b in the absence of CD4.
Binding of gp120 and o-gp140 to 17b in presence and
absence of CD4 is shown (Figs. 6C–F). The kinetic data
indicate that both gp120 and gp120ΔV2 bind to 17b in the
absence of CD4 with nanomolar affinity (Table 2).
Interestingly, in the absence of CD4, both o-gp140 and o-
gp140ΔV2 exhibit similar affinities for 17b but have
roughly 3-fold weaker affinity compared to monomers
(Table 2).
In the presence of CD4, the 17b epitope was up-regulated
in all Envs (Figs. 6D, F); up-regulation was approximately 2-
fold for gp120 and gp120ΔV2 (Figs. 6C, D) and was greater
than 4-fold for o-gp140 and o-gp140ΔV2 (Figs. 6E, F). The
affinities of Envs for 17b in the presence of CD4 could not be
accurately determined due to the extremely high affinity of
binding (Figs. 6D, F).
Immunogenicity studies
We evaluated these Envs for their ability to induce
antibody responses in rabbits. Groups of rabbits were
immunized in a DNA prime and protein boost regimen.
All of the animals induced Env-specific antibodies after
three DNA immunizations (data not shown), which were
substantially enhanced after the protein boost (Fig. 7A). To
assess the quality of these binding antibodies, we deter-
mined the proportion of antibodies directed against the CD4
binding site. Animals primed with o-gp140ΔV2 DNA
followed by o-gp140ΔV2 protein boost induced the highest
percentage of antibodies directed against the CD4 binding
site (Fig. 7A).
We also determined the relative proportion of antibodies
directed against total and linear epitopes. Animals primed
with o-gp140 and o-gp140ΔV2 and boosted with o-
Fig. 4. Isothermal titration calorimetry (ITC) is used to measure the heat of the reaction between four-domain CD4 and Env in free solution: (A) gp120, (B) gp120ΔV2,
(C) o-gp140 and (D) o-gp140ΔV2. All titrations were performed in duplicate with the heat of mixing and dilution subtracted from the final data. The top panels
represent the raw data (power:time). The bottom panels represent integrated areas per mole of injected ligand (envelope) as a function of molar ratio. Note that, for the
trimeric envelope proteins, the number of CD4 binding sites (n) cannot be determined by the x axis (see Materials and methods). The solid line represents the best
nonlinear fit to the experimental data.
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towards the conformational epitopes compared to either
gp120 or gp120ΔV2 primed animals (Fig. 7B). Thedifference in titers against linear epitopes between the
gp120ΔV2 monomer and o-gp140 and o-gp140ΔV2 was
statistically significant (P < 0.05).
Fig. 5. Env/CD4 titration followed by size exclusion HPLC defines the number of active binding sites. (A) A typical profile of mixtures of o-gp140ΔV2SF162 to CD4
at different molar ratios at 25 °C. The interpretation of the data for different mixtures is presented by envelope trimers (circles) and sCD4 monomers (crescents). The
trimeric protein continues to bind the titrant (CD4) until a molar ratio of 1:3 is observed, confirming that all three CD4 binding sites on the trimer are active and
saturated. (B) Molar fractions of gp120, CD4 and the complex were calculated from peak area for each component from a chromatograph of gp120 titrated with a ten-
fold concentration range of sCD4; (C) gp120ΔV2 titrated with a ten-fold concentration range of sCD4 and (D) o-gp140 titrated with a ten-fold concentration range of
sCD4, with the molar fraction of trimer calculated as the number of potential CD4 binding sites.
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induced by different forms of Env, we determined the
proportion of antibodies directed against linear V3 epitopes.
Priming with gp120ΔV2 and boosting with o-gp140ΔV2
induced four-fold higher antibody titers to linear V3 epitopes
compared to gp120 (Fig. 7C). In addition, priming with o-
gp140ΔV2 and boosting with o-gp140ΔV2 induced the lowest
responses against linear epitopes in the V3 loop. Avidity of
antibodies induced by different Envs was measured (Fig. 7D).
At 4 weeks post-final DNA immunization, the antibody
avidities were relatively low for all groups. However, at
4 weeks post-final protein boost, the avidities were highest for
o-gp140 and o-gp140ΔV2 primed and o-gp140ΔV2 boosted
groups compared to gp120 and gp120ΔV2 primed and o-
gp140ΔV2 boosted groups (Fig. 7D).
Discussion
Designing an immunogen for use as an HIV vaccine
remains a challenge, in large part due to the lack of
understanding of the attributes necessary to design aneffective immunogen capable of inducing protective neutral-
izing antibody responses. As HIV Env is currently the best
candidate for such a vaccine, we analyzed the biophysical,
biochemical and immunological properties of different Envs
and attempted to correlate structural data to immunogenicity
to establish structure–function relationships.
The apparent affinity, kinetics and thermodynamics of the
CD4–Env interaction were defined by SPR and ITC. The
interaction between CD4 and the engineered Envs was of high
affinity (nanomolar), with the trimers binding approximately 3-
fold tighter to CD4 than their corresponding monomers as
measured by SPR. In addition, there was strong favorable Gibbs
free energy of binding for all four Envs as measured by ITC.
Using Envs (gp120, o-gp140 or o-gp140ΔV2) either as a ligand
or an analyte in SPR yielded similar affinities for the resulting
complexes, thus confirming the results.
Similar to previous findings (Stites et al., 1997), we observed
slow rates of association for Env to CD4 by SPR along with
large entropic costs of association as measured by ITC. These
data confirm that significant molecular rearrangements take
place in Env upon binding to CD4 as observed in previous
Fig. 6. Probing of Env structure with monoclonal antibodies. b12 binding observed by SPR for: (A) gp120 and (B) o-gp140. 17b binding for (C) gp120, (D) gp120–
CD4 complex, (E) o-gp140, and (F) o-gp140–CD4 complexes. The concentration ranges for HIV Env were 5 to 1000 nM. As a negative control, we used a control
surface coupled to 1000 RUs of BSA (Pierce). All measurements were taken in duplicate or triplicate.
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affinities measured by SPR, as well as enthalpies and Gibbs free
energies calculated from ITC data for all the Envs were
remarkably consistent with previous studies despite using
gp120 from a different isolate, using four-domain rather than
two-domain CD4 and performing experiments under different
conditions (Myszka et al., 2000; Pancera et al., 2005). These
data suggest that these biophysical techniques are quite robust
and should be used in characterization of novel immunogens.
There is a wealth of data demonstrating that recombinant
Env binds to CD4 (Kwong et al., 1998; Myszka et al., 2000;
Sattentau and Weiss, 1988; Trkola et al., 1996a; Srivastava et
al., 2002, 2003), however, there is no clear evidenceTable 2
SPR studies of envelope binding to b12 and 17b monoclonal antibodies
Proteins
tested
SPR measurements
b12 ligand, Env analyte 17b ligand, Env analyte
Ka (1/μM) Kd (nM) Ka (1/μM) Kd (nM)
gp120 39 26 512 2
gp120ΔV2 2 446 508 2
o-gp140 113 8.8 142 7.0
o-gp140ΔV2 159 6.3 135 7.4
For kinetic analysis, SPR sensorgrams were fitted simultaneously to a single-site
conformational change-binding model by using a nonlinear data analysis
program (Biaevaluation 4.01, Biacore AB, Uppsala, Sweden). All kinetic
parameters reported were repeated in duplicate or triplicate.demonstrating if three or fewer CD4 binding sites in a trimer
are accessible for CD4. Molecular modeling of a trimeric Env
based on the monomeric structure suggests that all three binding
sites would be accessible to surface expressed CD4, and CD4:
CD4 steric hindrance may not occur due to large spacing
(∼200 Å) between the receptor molecules (Kwong et al., 2000).
With the use of SEC-HPLC, we have demonstrated that
each individual monomer in a trimer had an intact CD4
binding site regardless of the presence or absence of the V2
loop. The stoichiometry determined by ITC is in agreement
with the data obtained in SEC-HPLC if we adjust the
concentration of functional Env (non-aggregated material),
thereby demonstrating the importance of post-ITC titration
analysis of the material.
Large binding enthalpies that favor association are indicative
of multiple binding interactions, whereas large entropies
unfavorable to association are indicative of large structural
rearrangements and a loss of structural freedom (Myszka et al.,
2000). It has been suggested that the large structural
rearrangement that Env undergoes upon CD4 binding may
inhibit B cell recognition and induction of high affinity
antibodies especially in the case of the unliganded Env (Chen
et al., 2005; Kwong, 2005). Differences in enthalpies were
observed especially between the monomers (gp120 and
gp120ΔV2) and the trimers (o-gp140 and o-gp140ΔV2)
(trimers yielding roughly 2-fold higher enthalpies favoring
binding to CD4 than the corresponding monomers).
Fig. 7. Quantity and quality of antibodies induced in rabbits in prime boost regimen: (A) total anti-Env antibodies and percentage of antibodies directed against CD4
binding site 4 weeks post-second protein boost. (B) Comparison of proportion of antibodies directed towards total and linear epitopes induced by different Env. (C)
Antibody responses directed against the linear V3 epitope and the ratio of antibodies directed against linear epitopes in V3 loop vs. all linear epitopes. (D) Avidity of
antibodies induced by different immunogens in DNA prime and protein boost regimen.
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association were observed. A large entropic cost for the
association of the gp120 monomer with CD4 is supported by
modeling calculations (Hsu et al., 2005) and has been attributed
to formation of intermolecular hydrogen bonds and hydropho-
bic contacts due to conformational rearrangement of the
bridging sheet in gp120 upon binding (Hsu et al., 2005;
Myszka et al., 2000). This model is supported by recent
elucidation of the apo gp120 core structure (Chen et al., 2005)
that suggests through large movements and rotations that the
bridging sheet forms when Env is liganded to CD4. To our
knowledge, entropic cost of structural rearrangement upon
binding for the soluble trimeric Env has not previously been
reported. It is noteworthy that, in the case of gp120ΔV2 and o-
gp140ΔV2, the magnitude of entropy is greater, suggesting that
in the context of the V2 loop deletion, o-gp140ΔV2 undergoes
more structural rearrangement.
The trimers produced by using the trimerization domain in
the gp41 in this study have all three CD4 binding sites intact and
have a strong affinity for CD4. Pancera et al. (2005) foundsomewhat relatively weaker binding for an engineered soluble
trimer expressed in Drosophila using GCN4 as a trimerization
domain for gp120 subunits (Kd = 65 nM). Interestingly, unlike
the trimeric proteins we constructed using a fused gp41 domain,
the GCN4 linked trimers appeared to bind only two molecules
of sCD4 unless multiple variable loops were deleted, suggesting
that access to all three binding sites may be linked to the
orientation of the monomers provided by gp41.
The affinities of Env for CD4 measured by ITC did not
reflect the tighter binding of the trimers versus the monomers
as observed by SPR. There are several potential explanations
that may account for these differences: (i) differences in
experimental conditions, in ITC the interaction takes place in
aqueous phase, while in SPR Env protein is coupled to solid
phase, and therefore more stable albeit with lesser degrees of
freedom, (ii) aggregation of the envelope protein at high
concentrations may play a role in affinity measurements in
ITC and (iii) ITC is relatively limited at measuring higher
affinity (nanomolar) interactions in the absence of competi-
tion. It is also important to note that multivalent binding of a
140 V.A. Sharma et al. / Virology 352 (2006) 131–144trimeric Env to CD4 is not likely to be observed in SPR
experiments due to steric hindrance and/or orientation of the
interacting partners, thus apparent affinities measured by SPR
may be indicative of only one or two sites on a trimer despite
all three sites being active in ITC.
Monoclonal antibodies were used to probe the exposure
of important epitopes to elucidate the differences or lack of
differences in the structure of different Envs using SPR.
Data obtained using the b12 antibody indicated that this
epitope was preserved and properly exposed on all Envs to
a similar extent, with the exception of gp120ΔV2. Similar
to the CD4 binding experiments, gp120ΔV2 yielded a much
higher maximum association signal by SPR. However, the
affinity of gp120ΔV2 for b12 was approximately 20-fold
less compared to gp120. The affinity for the b12 antibody
was at least 3-fold tighter for o-gp140 and o-gp140ΔV2
compared to gp120 and gp120ΔV2, possibly an indication
of avidity or better exposure or preservation of this epitope
on trimers compared to monomers.
All four proteins exhibited similar magnitudes of binding
to 17b (after normalizing data for molecular weight) in the
presence or absence of CD4. The trimeric proteins o-gp140
and o-gp140ΔV2 exhibited a 3-fold weaker affinity compared
to corresponding monomers. It is possible that not all the
CD4i epitopes are accessible in a trimer or the binding site
may be altered by oligomerization. Both monomeric proteins
gp120 and gp120ΔV2 up-regulated 17b binding by two-fold
in the presence of CD4, whereas the trimeric proteins o-
gp140 and o-gp140ΔV2 up-regulated the epitopes at least
four-fold.
By normalizing the CD4 and b12 SPR data for molecular
weight of different Env analytes, we observed 3-fold greater
magnitude of association as reflected by higher RU for gp120
compared to o-gp140 and o-gp140ΔV2. These data suggest
that 3-fold fewer trimer molecules can bind to the surface
most likely due to steric hindrance caused by the larger size
of the trimer. However, we observed a different behavior for
gp120ΔV2 where normalized maximum RU levels for CD4
and b12 are 3-fold higher than for gp120 and nearly 10-fold
higher than for the trimers. Additionally, data obtained for
CD4 binding to gp120ΔV2 were difficult to fit to a single-site
binding model suggesting either gp120ΔV2 represents a
heterogeneous population of structures or its structure is
altered compared to the other three Env structures. When we
performed the reverse SPR experiment using gp120ΔV2 as a
ligand (coupling to the solid phase) and CD4 as an analyte,
no binding is observed in contrast to the other Env proteins.
Furthermore, ITC titrations of gp120ΔV2 and CD4 suggest
that approximately 20–50% of gp120ΔV2 is inactive. These
data suggest that indeed the structure of gp120ΔV2 is altered.
These data taken together suggest that the V2 deletion in
the monomer allows a functional albeit altered CD4 binding
site. This deletion may also affect folding in other parts of
the molecule, allowing increased number of molecules to
bind in SPR analysis and a higher proportion of inactive
molecules as measured by ITC. In contrast, CD4 binding
measured by SPR and ITC, and b12 and 17b bindingmeasured by SPR remained relatively unchanged in o-
gp140ΔV2 relative to o-gp140. This suggests that, in the
context of the trimer, the V2 deletion does not greatly alter
the structure as it does in the context of the monomer.
Interestingly, maximum normalized RU measured by SPR
for 17b both in the presence and absence of CD4 appears to
be unaffected by the V2 deletion for both monomer and
trimer as they respond similarly to gp120 and o-gp140 in
this assay. This suggests that the 17b epitope is rather
unaffected by the V2 deletion compared to the CD4 binding
site.
Priming with gp120ΔV2 induced a higher proportion of
antibodies directed against all linear epitopes and linear epitopes
in the V3 loop than priming with other Envs. For linear
epitopes, the increase in titer was significant compared to
antibodies induced by the trimers (P < 0.05). However,
differences between gp120 and gp120ΔV2 were not significant
(P = 0.06).
We understand that priming with different Envs and
boosting all the animals with o-gp140ΔV2 protein is not
ideal. However, it is interesting to note that, despite priming
the animals with different Env DNA constructs and boosting
them with the same (o-gp140ΔV2), we still observed a
statistically significant difference in the anti-Env antibodies
induced by different structures. We expect that priming and
boosting the animals with matched constructs such as
gp120ΔV2 would greatly enhance the qualitative differences
observed compared to animals primed with gp120ΔV2 and
boosted with o-gp140ΔV2.
Affinity of CD4 binding correlated with proportion of the
antibodies induced against the conformational epitopes.
Biophysical analysis of gp120ΔV2 suggests that it may be
partially inactive or heterogeneous, consistent with induction
of higher proportion of antibodies directed against linear,
and other non-functional epitopes. Furthermore, biophysical
analysis reveals that the V2 deletion has broad structural
implications in the monomer not shared by the trimer, and
these changes are reflected in the quality of the immune
response. This study demonstrates that designed features of
engineered immunogens should be examined using biophy-
sical techniques as it may be relevant in predicting the in
vivo efficacy and provide an important tool for character-
izing and selecting an effective vaccine candidate for further
evaluation in preclinical studies. This is the initial attempt to
establish a correlation between biophysical properties and
immunogenicity of a designed immunogen, further studies
with optimized regimens and larger sample sizes will be
needed to confirm these initial findings.
Materials and methods
Envelope plasmid construction
The sequences encoding the open reading frame of the
ectodomain of the Env protein from the HIV-1 SF162 and
HIV-1 SF162ΔV2 isolates were optimized for higher
expression, as described earlier (Srivastava et al., 2002),
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DNA fragment. Human tissue plasminogen activator (TPA)
signal sequence was added for efficient secretion. To
stabilize the Env proteins in a trimeric conformation, we
introduced a series of mutations in the primary and
secondary protease cleavage sites in the Env polypeptides
(Srivastava et al., 2003). The resulting Env expression
cassettes (gp120SF162, gp120SF162ΔV2, gp140SF162 and
gp140SF162ΔV2) were cloned into the pCMV3 expression
vector for both transient expression and the development of
stable CHO cell lines.
Development of stable CHO cell lines secreting HIV SF162
envelope proteins
Stable CHO cell lines secreting gp120SF162, gp120-
ΔV2SF162, gp140SF162 and gp140SF162ΔV2 were derived
by using DG-44 cells with a double deletion in the dihydrofolate
reductase gene following the experimental protocol described
elsewhere (Srivastava et al., 2003, 2002).
Production of HIV envelope proteins
The CHO cell clones producing the Env proteins of interest
were bioreactor-adapted in low serum containing media,
selected for the best clone for each protein and grown in 12 l
production bioreactors. Bioreactors were monitored daily for
cell density, pH, CO2 and O2 concentration. Collected media
were concentrated 20-fold through a 100-kDa pore-size
membrane filter and stored at −80 °C in the presence of
1 mM EDTA and 1 mM EGTA.
Purification of envelope proteins
All the envelope proteins were purified as described
elsewhere in detail using a combination of lectin capture and
ion exchange columns (Srivastava et al., 2003). During the
purification process, fractions were analyzed by polyacrylamide
gel electrophoresis (PAGE) both under reducing and denaturing
and under native conditions following standard methods and
also in a CD4 receptor-binding assay (Srivastava et al., 2002,
2003). Gels were stained with Coomassie brilliant blue or
processed for immunoblotting. All the fractions containing Env
monomer with and without V2 loop were pooled, concentrated
and stored frozen at −80 °C. Peak fractions containing o-
gp140SF162 and o-gp140 SF162ΔV2 were pooled, concen-
trated and fractionated on a 16 × 90 mm Superdex-200 column
(Pharmacia) equilibrated with 10 mM NaCitrate plus 300 mM
NaCl to separate monomer from trimer. The fractions contain-
ing Env protein in trimeric conformation were pooled,
concentrated and kept frozen at −80 °C until used.
Surface plasmon resonance (SPR) assay
CD4 binding assay
Surface plasmon resonance assays were performed using a
BIACORE 3000 optical biosensor system (Biacore AB,Uppsala, Sweden). To perform the kinetic study of the binding
of Env to CD4, CD4 was immobilized using amine coupling
onto CM5 sensor chip (BIAcore AB, Uppsala, Sweden) to attain
1000 response units (RUs). Association was assessed by
flowing different Envs (5 to 1000 nM) over the chip at a flow
rate of 25 μl/min. Signal from a reference cell coupled to BSA
was subtracted from the specific responses. The association and
dissociation phase data for double injections of five concentra-
tions of analyte were fitted simultaneously to a single-site
conformational change-binding model using Biaevaluation 4.01
(Biacore AB, Uppsala, Sweden).
The reverse experiment was performed by immobilizing Env
proteins to CM5 chip using amine coupling reaction to attain
800–1200 RUs. The assay was performed as described above.
mAbs binding assay
To perform mAb binding to Env, b12 and 17b mAbs were
immobilized using amine coupling onto CM5 sensor chip to
attain 1000 RUs, and the assay was performed under the
experimental conditions described as above.
Isothermal titration calorimetry (ITC)
Isothermal titration calorimetry was performed on a VP-ITC
(MicroCal LLC, Northampton, MA) using a 1.4 ml cell and a
0.25 ml syringe. Proteins were dialyzed extensively in PBS
containing 0.005% Tween and concentrated using a stir cell
(Millipore Inc.) prior to loading. Three to five micromolar CD4
was loaded in the cell, with 18- to 30-μM envelope protein in
the syringe. Titrations were performed using 15 μl injections
with 5-min delay between each injection. All runs were adjusted
for heat of dilution and mixing by subtracting a blank run of
envelope titrated into buffer only. Binding isotherms obtained
were auto-fitted to a baseline using Origin® software (MicroCal
LLC, Northampton, MA). Using a floating number of binding
sites, isotherms were best fit to a single set of binding
parameters. Fits were generated using the Origin® 7.0 software
parameter “ligand in cell” option, thus generated figures for the
trimers do not reflect the n values on the x axis as the software
does not re-calculate the molar ratio on the figure but does
reflect the change in the fit obtained (MicroCal LLC).
Size exclusion chromatography
All titrations were performed at 25 °C in PBS pH 7.4.
Mixtures containing different ratios of Env and CD4 were
prepared, incubated for 15 min at room temperature and injected
onto a pre-equilibrated Bio Sil SEC 250 gel filtration HPLC
column (Bio-Rad Laboratories). Samples were run in 20 mM
NaH2PO4 and 400 mM ammonium sulfate (pH 6.0) at a flow
rate of 1 ml/min, and absorbance was measured at 214 nm using
a Photodiode Array Detector (Waters Corporation, Milford,
California). Molar fraction was determined by integrating the
corresponding peak area for each component of the mixture.
500 nM o-gp140ΔV2 was titrated with a range of 500 nM to 2.5
μM sCD4, 500 nM gp120 SF162 was titrated with a range of
5 nM to 2.5 μM sCD4, 500 nM gp120ΔV2SF162 titrated with
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150 nM to 15 μM sCD4.
Immunogenicity study
Age- and weight-matched New Zealand female rabbits (4
rabbits per group) were immunized intramuscularly with 1 mg
of plasmid DNA corresponding to o-gp140, o-gp140ΔV2,
gp120 and gp120ΔV2 at 0, 4 and 12 weeks using a biojector.
On weeks 24 and 36, all the animals irrespective of prime were
boosted with 50 μg of o-gp140ΔV2 protein in MF59 at two
sites (250 μl each). These rabbits were bled regularly at 2-week
intervals until the completion of the study, and serum was
collected and analyzed for binding and neutralizing antibodies.
Measurement of antibody responses
Total antibody responses
To determine the total antibodies, ELISA was performed on
serum samples collected every 2 weeks, as described previously
(Srivastava et al., 2002).
Linear antibody responses
To determine the antibodies induced against the linear
epitopes, HIV Env protein was denatured and reduced in 0.1%
SDS and 10 mM DTT by boiling for 3–5 min. The ELISA
plates were coated with 100 ng of the reduced and denatured
protein and the assay performed as described elsewhere in detail
(Srivastava et al., 2002).
Anti-peptide ELISAs
To determine the antibody responses directed against linear
V3 epitopes, appropriate peptides derived from the V1, V2 and
V3 loops were synthesized, reconstituted in PBS at pH 7.4 and
used to coat the ELISA plates at 1 μg/well. All other steps were
performed as described elsewhere in detail (Srivastava et al.,
2002).
Determining the proportion of antibodies directed against CD4
binding site
To determine the proportion of antibodies directed against
the CD4 binding site, the ELISA plates were coated with 100 ng
of trimeric Env protein as described above. After blocking the
non-specific binding sites, half the Env coated wells in each
plate were incubated with 1 μg of sCD4 (four domain). The
wells were washed, and all the sera samples were tested in
duplicate (one without CD4 and other with CD4). All other
steps were performed as described above. We have compared
the ELISA titers obtained for individual serum sample in the
presence and absence of CD4. The difference in titers in
presence of CD4 was presented as % of antibodies directed
against the CD4 binding site.
Antibody avidity index
Antibody avidity index determination was performed using
an ammonium thiocyanate displacement (NH4SCN) ELISA as
described elsewhere (Srivastava et al., 2002).Acknowledgments
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